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Introduction
Recent concerns about bioterrorism 
and emerging diseases have led to 
a new focus on the development 
of vaccines and drugs targeting 
infectious pathogens. An important 
component of vaccine development 
is the characterization of immune 
responses (to vaccination, for 
example, or following infection in 
experimental settings) by evaluating 
the epitopes recognized by antigen-
speciﬁ c receptors of the immune 
system (antibodies and/or T cell 
receptors (TCRs)) [1]. In recent 
years, different groups have followed 
different approaches to the discovery 
of immune epitopes, and various assay 
types have been used to generate data 
for the purpose of epitope deﬁ nition 
or validation. We believe that research 
in this area could be greatly facilitated 
by a comprehensive knowledge center: 
a repository of immune epitope data 
with associated analysis tools. Our goal 
is the creation of the Immune Epitope 
Database and Analysis Resource 
(IEDB). 
The IEDB is sponsored by the 
National Institute for Allergy and 
Infectious Diseases (NIAID). It will host 
data relating to both B cell and T cell 
epitopes from infectious pathogens, as 
well as experimental and self-antigens 
(RTP-NIH-NIAID-DAIT-03/31; www.
niaid.nih.gov/contract/archive). 
Priority will be placed on those epitopes 
considered to be potential bioterrorism 
threats, and emerging diseases as 
deﬁ ned by NIAID (so-called category 
A–C pathogens; see: http:⁄⁄www2.niaid.
nih.gov/Biodefense/bandc_priority.
htm). As a corollary to the IEDB effort, 
NIAID has also launched a large-scale 
antibody and T cell epitope discovery 
program aimed at generating epitope 
data and analysis resources to be 
included in the IEDB. Other data 
sources to be integrated into the IEDB 
are publications in peer-reviewed 
journals, published patents or patent 
applications, and direct submissions 
from institutions or companies. 
Everyone who contributes data or 
analysis resources to the database 
will be cited, either by authorship or 
by other acknowledgment of their 
contributions.
The involvement of the scientiﬁ c 
community in the design of  the 
scope and capability of the IEDB 
will be crucial to the success of the 
project. The IEDB will be produced 
in a manner that encourages the 
incorporation of data and analytical 
tools derived by research labs at-large. 
With this paper, we hope to inform 
the scientiﬁ c community of our effort 
and to solicit feedback while the 
project is still in a design stage. We 
envision that this resource center will 
be freely available on the Internet, with 
a prototype operational in the fourth 
quarter of 2005. Once the project is 
online, forms for direct feedback and 
online submission of data and tools 
will be provided. Yearly conferences 
to present data relating to epitope 
identiﬁ cation and the IEDB itself will 
be organized, and a newsletter will be 
published quarterly.
Defi ning the Scope of the IEDB
Each scientiﬁ c approach generates 
a set of epitope data, speciﬁ c to 
itself, which must be integrated into 
a general representation of epitope 
information. In a programmatic 
sense, we believe that selecting 
data that ﬁ t one particular epitope 
deﬁ nition or experimental bias is 
not our prerogative and would be 
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Figure 1. Main Classes in the IEDB
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unwise. Rather, we have opted to 
deﬁ ne a comprehensive, all-inclusive 
representation of information that 
separates epitope features into intrinsic 
and extrinsic features. Intrinsic 
features are those determined by the 
sequence and structure of an epitope, 
while extrinsic features are context-
dependent attributes determined 
by the experimental or natural 
environment. This immunological 
perspective will be an organizing 
principle behind the IEDB.
Intrinsic Versus Extrinsic Features 
of an Epitope
At the level of T cell epitopes, intrinsic 
features included in the IEDB are: the 
molecular structure of the epitope, 
the binding afﬁ nity for different MHC 
receptors, and the afﬁ nity of MHC/
epitope complexes for TCRs of deﬁ ned 
sequence. Likewise, at the level of B 
cell epitopes, intrinsic features include 
the epitope’s molecular structure and 
binding afﬁ nity for antibody molecules 
of deﬁ ned sequence. These features 
are unequivocally speciﬁ ed and are 
singularly associated with a given 
epitope structure or epitope/receptor 
combination. 
Other features—such as 
immunogenicity, or whether an 
epitope is naturally processed—are 
not intrinsically associated with a 
given molecular structure of an 
epitope alone, but rather are context-
dependent (i.e., extrinsic). Context 
information includes, for example, 
the species of the host in which a 
response was found, the assay utilized 
to measure responses, and the dose 
and route of administration. Likewise, 
the yield of a given epitope following 
proteasomal cleavage of a complex 
protein precursor is dictated by the 
overall sequence of the protein in 
which the epitope is contained. Also, 
the T cell and B cell responses to an 
epitope are heavily inﬂ uenced by 
previous exposure of the immune 
system to the same or a related 
antigen. Collectively, these examples 
show that to meaningfully capture the 
immunogenicity of an epitope, the 
context in which it occurs must be 
described as well. 
The IEDB Classes
Formalizing the above considerations, 
we deﬁ ned the main classes of the 
IEDB data as  Reference, Epitope, 
Binding, and Context (Figure 1). These 
classes represent the top level in the 
data hierarchy used to store epitope 
information in the IEDB. The class 
Reference deﬁ nes one of three possible 
sources of data, namely literature, 
patent, and direct submissions. The 
Epitope class is subdivided into two 
categories: Epitope Structure, which 
speciﬁ es the molecular structure of 
an epitope itself, and Epitope Source, 
which identiﬁ es the pathogen/protein 
in which the Epitope is present. 
The Binding class captures intrinsic 
information relating to how the 
structure speciﬁ ed in the “Epitope” 
class interacts with well-deﬁ ned 
receptors of the immune system such 
as MHC molecules or antibodies 
and TCRs of deﬁ ned sequence. The 
Context class is organized into three 
subclasses, including T cell immune 
responses, naturally processed peptides, 
and B cell immune responses. Table 1 
is an example how the main features of 
a T cell epitope described in [2] would 
be displayed in the IEDB. Many more 
ﬁ elds exist that are left blank because 
they are not appropriate for this 
particular epitope (such as antibody 
binding data) or are unknown (such as 
MHC binding data).
A Scientifi c Approach for 
the Development of the 
Analysis Resource
Our proposal includes the 
establishment and maintenance of 
an Analysis Resource of online tools 
for the Immune Epitope Database. 
Because this resource must be useful to 
the entire community, it is important 
that the tools provided cover a broad 
range of research areas relating to 
epitope discovery and analysis, and that 
no particular scientiﬁ c “school” has 
priority. To identify tool candidates, we 
have generated a list of existing tools 
of interest through extensive literature 
searches and expert input. This will be 
periodically revised, taking advantage 
of input from the scientiﬁ c community 
and NIAID. 
The current list of candidate tools 
comprises an extensive menu of 
prediction tools for the identiﬁ cation 
of novel antibody and T cell epitopes 
from genome and protein sequences. 
At the level of antibody epitope 
predictions, standard methods of 
predicting which regions in a protein 
are likely to be on the surface will 
be provided, such as hydrophilicity 
analysis. Tools that use various methods 
for prediction of MHC binding will 
also be provided, along with tools 
predicting proteasomal processing and 
TAP transport of T cell epitopes. 
We will also provide analytical tool 
resources to assist in vaccine discovery 
and development. These are designed 
to project population coverage of 
epitopes in different ethnicities, to 
project the degree of cross-reactivity 
within sets of different MHC molecules, 
and to assess the degree of conservancy 
of an epitope in various isolates of 
the same pathogen, both in related 
pathogens, and in potential hosts. 
Finally, tools to visualize data will be 
provided, such as those that display 
antibody antigen interactions where 3D 
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Table 1. Sample Epitope Entry in the IEDB
Main Class Subclass Sample Fields Information Captured
Reference Type Journal article
Authors Oldstone et al.
Journal J Exp Med
Date 1988
Epitope Structure Molecular structure Peptide
Sequence VENPGGYCL
Source Source species LCMV ARM
Source protein GP
Position in protein 278–286
Context (T-Cell) Immunization Immunization type Infection
Host species C57BL/6 mice
Immunogen LCMV ARM
Assay Effector cells CTL clones
Target cells Mouse cell lines
MHC restriction H2-Db
Response measured Cell lysis (positive)
Assay type 51Cr release
DOI: 10.1371/journal.pbio.0030091.t001
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structural information is available. We 
also hope that collection of consistently 
annotated data in the IEDB will allow 
the development of new, “context-
sensitive,” tools.
In deciding how many tools 
should be hosted in the IEDB, a 
balance has to be achieved between 
discriminating too much, which may 
leave user demands unaddressed, and 
discriminating too little, hosting so 
many tools that the collection becomes 
overly redundant and unmanageable. 
To facilitate an objective and 
transparent choice of which predictive 
tools should be hosted, the predictions 
of all candidate tools will periodically 
be evaluated. Most importantly, we 
plan to make all evaluations publicly 
available through the IEDB website, 
and we will encourage all different 
scientiﬁ c groups to participate by 
submitting tools and evaluating data. 
Such prediction “contests” have 
had a tremendous positive impact 
in the ﬁ eld of tool evaluation and 
prediction of protein structure [3,4]. 
To the best of our knowledge, this 
would represent the ﬁ rst attempt 
at a rigorous and comprehensive 
evaluation of prediction tools found 
on immune responses.
Conclusions
We envision a future in which the 
development of the Immune Epitope 
Database and Analysis Resource will 
help researchers throughout the world 
quickly access relevant information 
for evaluation of immune responses, 
assisting them in the development of 
prophylactic/therapeutic approaches 
against new and old, emerging and 
reemerging diseases. 
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